HOME >> BIOLOGY >> NEWS
From clinical cancer research: rethinking therapeutic cancer vaccine trials

Ongoing therapeutic cancer vaccine trials have yet to show evidence of vaccines spurring a patients immune system to shrink tumors -- yet patients who receive these vaccines in trials tend to live longer and respond better to subsequent treatment. In the July 1 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, a team of National Cancer Institute researchers asks a fundamental question: are we looking at cancer vaccine trials the wrong way"

In a review of five prostate cancer vaccine trials, NCI researchers offer evidence that patients who receive vaccines may respond better to subsequent chemotherapy or hormone treatment. The specific results or endpoints of these clinical trials, however, were not the long term survival of patients, but rather the degree to which the vaccine caused tumors to shrink. According to the researchers, since they didnt achieve their primary endpoints, these vaccines may be abandoned as dead-ends, despite their real therapeutic value in terms of prolonging patient survival.

Clinical data are providing evidence that patients are living longer following vaccination, de-spite the fact that trials do not show the vaccines can induce the immune system into shrinking tumors, said Jeffrey Schlom, Ph.D., chief of the Laboratory of Tumor Immunology and Biology at the National Cancer Institute. The data suggests that the scientific community and regulatory committees ought to rethink the design of clinical vaccine trials and our current approach to measuring the effectiveness of a cancer vaccine.

According to the researchers, it may be more helpful to think of the effectiveness of a vaccine in terms of the response of the patient, rather than the response of the tumor. While the Response Criteria in Solid Tumors (RECIST) experimental standards works well in evaluating therapies that are toxic to tumors, such as radiation or chemotherapy, they are less capable of me
'"/>

Contact: Greg Lester
lester@aacr.org
267-646-0554
American Association for Cancer Research
3-Jul-2007


Page: 1 2

Related biology news :

1. Preclinical study links gene to brain aneurysm formation
2. Gene variant is associated with brain anatomy, clinical course of ADHD
3. New joint replacement material developed at MGH put to first clinical use
4. Serica scientists win AOSSM Award for ACL (knee) tissue regeneration in preclinical study
5. Manganese levels increase in scrapie-infected sheep before clinical symptoms develop
6. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
7. Alzheimers drug based on Purdue -- designed inhibitor begins clinical trials
8. UT Southwestern joins national clinical trial to uncover long-term effects of West Nile virus
9. BDSI announces positive phase III clinical trial results
10. Oncolytics Biotech Inc. proceeds to initiate US Phase II sarcoma clinical trial
11. NIH announces phase III clinical trial of creatine for Parkinsons disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/28/2020)... ... June 25, 2020 , ... ... announced that it has entered into a multi-year contract with Merus N.V., ... their translational and clinical research strategy to discover and develop ground-breaking drugs. ...
(Date:6/25/2020)... ... June 24, 2020 , ... eClinical Solutions ... data services that accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: ... hospitalized patients with severe COVID-19. This is the first study of an XPO1 ...
(Date:6/23/2020)... , ... June 23, 2020 , ... ... sustainable healthcare, and Renovagen Ltd, a UK supplier and manufacturer of innovative portable ... support testing operations in the fight against the COVID-19 pandemic in Zambia. , ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... ... July 08, 2020 , ... ... products, announces a significant expansion of laboratory operations through its COVID-19 testing ... implementing testing programs. , Bode-CARES provides a turnkey solution that ...
(Date:7/7/2020)... BOSTON (PRWEB) , ... July 06, 2020 , ... ... Innovative Practices Awards. Entries from Roche, Eli Lilly, Bristol-Myers Squibb, the University of ... Since 2003, Bio-IT World has hosted an elite awards program, highlighting outstanding examples ...
(Date:6/28/2020)... ... June 25, 2020 , ... With the COVID-19 pandemic ... drug treatment. In an effort to better understand the cellular responses to COVID-19, ... imaging dataset portraying therapeutic compound effects from over 1,600 approved and referenced molecules ...
(Date:6/23/2020)... ... June 22, 2020 , ... Regen Suppliers, ... offer. This includes buy three, get the fourth unit free with no limit ... derived exosomes, known as exosomes, have been a game changer for regenerative therapies. ...
Breaking Biology Technology:
Cached News: